72
Participants
Start Date
March 12, 2021
Primary Completion Date
July 20, 2023
Study Completion Date
July 20, 2023
AZD1402
Randomised participants will receive oral inhalation of AZD1402, via DPI.
Placebo
Randomised participants will receive oral inhalation of matching placebo via DPI.
Short acting beta agonist (SABA) (rescue medication)
"In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)"
Run-in medications (ICS-LABA combination)
"During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care."
Research Site, Kaohsiung City
Research Site, Herston
Research Site, Nedlands
Research Site, Csorna
Research Site, Szombathely
Research Site, Berlin
Research Site, Berlin
Research Site, Berlin
Research Site, Villarreal
Research Site, Berlin
Research Site, Santiago de Compostela
Research Site, Suwon
Research Site, Hamburg
Research Site, Incheon
Research Site, Namdong-gu
Research Site, Lübeck
Research Site, Cheongiu
Research Site, Bonn
Research Site, Frankfurt
Research Site, Melbourne
Research Site, Windsor
Research Site, Québec
Research Site, Hanover
Research Site, Bialystok
Research Site, Krakow
Research Site, Krakow
Research Site, Lodz
Research Site, Lubin
Research Site, Sopot
Research Site, Wroclaw
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Kiev
Research Site, High Wycombe
Research Site, Liverpool
Research Site, London
Research Site, London
Lead Sponsor
AstraZeneca
INDUSTRY